Provided by Tiger Trade Technology Pte. Ltd.

Akero Therapeutics

54.65
0.0000
Volume:- -
Turnover:836.20M
Market Cap:4.50B
PE:-14.61
High:54.65
Open:54.65
Low:54.65
Close:54.65
52wk High:58.40
52wk Low:21.34
Shares:82.32M
Float Shares:67.77M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7418
EPS(LYR):-3.7544
ROE:-34.53%
ROA:-22.63%
PB:4.70
PE(LYR):-14.56

Loading ...

Synox Therapeutics Strengthens Board of Directors With Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

THOMSON REUTERS
·
Oct 21, 2025

Akero Therapeutics CEO Andrew Cheng Reports Disposal of Common Shares

Reuters
·
Oct 15, 2025

TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76

MT Newswires Live
·
Oct 13, 2025

Why Biotech's Rally Can Last This Time -- Heard on the Street -- WSJ

Dow Jones
·
Oct 13, 2025

U.S. RESEARCH ROUNDUP-American Express, BlackRock, Domino's Pizza

Reuters
·
Oct 13, 2025

Hold Rating on Akero Therapeutics Amid NOVO Acquisition and Regulatory Uncertainties

TIPRANKS
·
Oct 11, 2025

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

Dow Jones
·
Oct 10, 2025

Post-Bell | Wall Street Closes Lower; Nvidia and Meta Gain 2%; AMD Drops 1%; Tilray Jumps 22%; Serve Robotics Surges 29%

Tiger Newspress
·
Oct 10, 2025

Akero Therapeutics Chief Scientific Officer Timothy Rolph Reports Disposal of Common Shares

Reuters
·
Oct 10, 2025

Analysts Conflicted on These Healthcare Names: Akero Therapeutics (AKRO) and HealthStream (HSTM)

TIPRANKS
·
Oct 10, 2025

Why Akero Therapeutics Stock Trounced the Market on Thursday

Motley Fool
·
Oct 10, 2025

Akero Therapeutics Inc - IF Deal Terminated Under Some Circumstances, Co to Pay $165 Mln Termination Fee to Novo Nordisk- SEC Filing

THOMSON REUTERS
·
Oct 10, 2025

Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

TIPRANKS
·
Oct 10, 2025

Akero Therapeutics Cut to Hold From Buy by Jefferies

Dow Jones
·
Oct 10, 2025

Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry

MT Newswires Live
·
Oct 09, 2025

Akero downgraded to Market Perform from Outperform at LifeSci Capital

TIPRANKS
·
Oct 09, 2025

Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties

TIPRANKS
·
Oct 09, 2025

Cautious Hold Rating on Akero Therapeutics Amid Acquisition Interest and Uncertainties in Efruxifermin’s Clinical Trajectory

TIPRANKS
·
Oct 09, 2025

Akero Therapeutics Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $56 From $75

THOMSON REUTERS
·
Oct 09, 2025

Canaccord Genuity Downgrades Akero Therapeutics to Hold From Buy

MT Newswires Live
·
Oct 09, 2025